The present invention relates to the field of molecular biology and cancer biology. Specifically, the present invention relates to a farnesyltransferase inhibitor (FTI) for use in methods of treating squamous cell carcinoma of the head and neck (SCCHN) that is either EGFR-inhibitory refractory or that has never been treated with an EGFR inhibitor, or for use in methods of treating lung squamous cell carcinoma (lung SCC) that is either EGFR-inhibitory refractory or that has never been treated with an EGFR inhibitor, in a subject, which methods include determining whether the subject is likely to be responsive to the FTI treatment based on HRAS mutation status in the subject.La presente invención se refiere al campo de biología molecular y la biología del cáncer. De manera específica, la presente invención se refiere a métodos de tratamiento de un sujeto con un inhibidor de farnesiltransferasa (FTI) que incluye determinar si es probable que el sujeto responda al tratamiento con FTI con base en el estado de mutación de HRAS en el sujeto.
